Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 41 to 50 of 369 total matches.
Antiviral Drugs for Influenza for 2023-2024
The Medical Letter on Drugs and Therapeutics • Nov 13, 2023 (Issue 1689)
.
Revised 11/1/23: See note on page 179.
The Medical Letter ® Vol. 65 (1689) November 13, 2023
178
Table ...
Influenza is generally a self-limited illness, but
pneumonia, respiratory failure, and death can
occur, especially in patients at increased risk for
influenza complications (see Table 1). Antiviral drugs
recommended for treatment and chemoprophylaxis
of influenza for the 2023-2024 season are listed in
Table 2. Updated information on influenza activity
and antiviral resistance is available from the CDC at
www.cdc.gov/flu.
Med Lett Drugs Ther. 2023 Nov 13;65(1689):177-82 doi:10.58347/tml.2023.1689a | Show Introduction Hide Introduction
Drugs for Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
) .................................. p 35
The Medical Letter ® Vol. 66 (1697) March 4, 2024
34
Systemic estrogen can also help ...
The primary symptoms of menopause are genitourinary
and vasomotor. The genitourinary syndrome
of menopause (GSM) includes symptoms such as
burning, irritation, dryness, dyspareunia, dysuria,
and recurrent urinary tract infection. Vasomotor
symptoms (VMS; hot flashes, night sweats) often
disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8 doi:10.58347/tml.2024.1697a | Show Introduction Hide Introduction
In Brief: New Benzodiazepine Warnings
The Medical Letter on Drugs and Therapeutics • Nov 02, 2020 (Issue 1610)
.
The Medical Letter ® Vol. 62 (1610) November 2, 2020
estazolam drug safety Doral diazepam Diastat clonazepam ...
The FDA now requires boxed warnings in the package
inserts of benzodiazepines describing the potential for
these drugs to be abused and misused and to cause
addiction and physical dependence. Benzodiazepine
labels have contained a boxed warning about a risk of
serious drug interactions with opioids since 2016.
PrabotulinumtoxinA (Jeuveau) for Frown Lines
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
pass between treatments
80
The Medical Letter ® Vol. 61 (1572) May 20, 2019
DRUG INTERACTIONS ...
The FDA has approved prabotulinumtoxinA-xvfs
(Jeuveau – Evolus) for temporary improvement in
the appearance of moderate to severe glabellar lines
associated with corrugator and/or procerus muscle
activity. Jeuveau is the fourth botulinum toxin
product to be approved in the US for this indication
(see Table 1). It has been available in South Korea as
Nabota since 2014.
Duaklir Pressair: Another LAMA/LABA Inhaler for COPD
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
. Tolerance
to the therapeutic effects of these drugs may
150
The Medical Letter ® Vol. 61 (1581) September ...
The FDA has approved Duaklir Pressair (Circassia), a
fixed-dose combination of the long-acting muscarinic
antagonist (LAMA) aclidinium bromide and the longacting
beta2-adrenergic agonist (LABA) formoterol
fumarate, for maintenance treatment of chronic
obstructive pulmonary disease (COPD). Aclidinium/formoterol is the fifth LAMA/LABA combination to be
approved in the US for this indication.
Annovera - A New Contraceptive Vaginal Ring
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
; backup contraception
regimens (Technivie or recommended
Viekira Pak)
198
The Medical Letter ® Vol. 61 ...
Annovera (TherapeuticsMD), a contraceptive vaginal
ring that releases segesterone acetate, a synthetic
progestin, and ethinyl estradiol, was approved by the
FDA in 2018 and is now available. It is the first product
to contain segesterone and the second vaginal ring
to become available in the US; NuvaRing, which
delivers etonogestrel and ethinyl estradiol, was the
first. Unlike NuvaRing, which requires use of a new
ring each month, the Annovera ring can be used for
an entire year, but it must be removed for one week
each month.
Minocycline Foam (Zilxi) for Rosacea
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020 (Issue 1611)
trials.
180
The Medical Letter ® Vol. 62 (1611) November 16, 2020
Table 2. Some Topical Drugs ...
The FDA has approved a 1.5% topical foam formulation
of minocycline (Zilxi – Foamix) for treatment of
inflammatory lesions of rosacea in adults. It is
the only topical minocycline product approved for
this indication. The same manufacturer markets
minocycline foam 4% (Amzeeq) for treatment of acne
in patients ≥9 years old.
Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
The Medical Letter ® Vol. 63 (1615) January 11, 2021
gastroparesis total symptom scores significantly
more ...
The FDA has approved Gimoti (Evoke), a nasal
spray formulation of the dopamine-2 (D2) receptor
antagonist metoclopramide, for relief of symptoms in
adults with acute and recurrent diabetic gastroparesis.
Metoclopramide (Reglan, and generics) has been
available for years in conventional and orally-disintegrating
tablets and in an injectable formulation.
It is the only drug that is FDA-approved for treatment
of diabetic gastroparesis.
Jatenzo - An Oral Testosterone for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
® Vol. 63 (1627) June 28, 2021
Increases in blood pressure can occur with Jatenzo;
patients taking ...
An oral formulation of testosterone undecanoate
(Jatenzo – Clarus) has been approved by the FDA for
treatment of adult men with conditions associated
with a deficiency of endogenous testosterone, such as
Klinefelter syndrome, orchiectomy, toxic damage from
chemotherapy or alcohol, or pituitary-hypothalamic
injury from tumors, trauma, or radiation. Jatenzo is
not approved for treatment of low testosterone levels
solely due to aging. It is the first oral testosterone
formulation to be approved in the US.
Dasiglucagon (Zegalogue) for Severe Hypoglycemia
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
. Pediatr Diabetes 2021; 22:734.
133
The Medical Letter ® Vol. 63 (1631) August 23, 2021
treated ...
The FDA has approved dasiglucagon (Zegalogue –
Zealand) for subcutaneous (SC) treatment of severe
hypoglycemia in patients ≥6 years old with diabetes.
Dasiglucagon is the third glucagon product to be
marketed in the US that does not require reconstitution
before administration; Gvoke, a SC formulation approved for use in patients ≥2 years old, and Baqsimi,
an intranasal powder approved for use in patients
≥4 years old, have been available since 2019.
Injectable glucagon emergency kits (GlucaGen
HypoKit, and generics) have been available for years,
but they require...